全球女性健康治療市場規模、佔有率、成長分析、依治療領域、依適應症、依配銷通路- 行業預測 2024-2031

2022年，全球女性健康治療市場規模為129.8億美元，預計將從2023年的137億美元成長到2031年的210.5億美元，預測期間（2024-2031年）複合CAGR為5.52%。

全球女性健康治療市場涵蓋多種藥物和治療方法，旨在解決女性在生命不同階段所面臨的獨特健康需求和課題。隨著人們對女性健康問題的日益關注，近年來，在意識提高、醫療技術進步和醫療保健政策不斷變化等因素的推動下，這個市場領域出現了顯著擴張。從生殖健康和避孕到更年期管理和骨質疏鬆症治療，市場提供了廣泛的治療選擇，以滿足女性的特定需求。近年來，人們更加重視針對主要影響女性的疾病的研發工作，例如乳癌和子宮頸癌、卵巢疾病以及狼瘡和類風濕性關節炎等自體免疫疾病等。此外，人們越來越認知到整體方法對婦女健康的重要性，其中不僅包括醫療干預措施，還包括生活方式的改變、心理健康支持以及獲得教育和預防性護理。儘管取得了重大進展，但女性健康治療市場仍然存在課題，包括獲得醫療保健服務的差異、臨床試驗中女性代表性不足以及圍繞某些健康問題的恥辱。應對這些課題需要醫療保健提供者、政策制定者、製藥公司和倡導團體的共同努力，以確保全世界婦女能夠公平地獲得優質護理並全面支持其健康需求。展望未來，全球女性健康治療市場的未來似乎充滿希望，醫學研究、技術和醫療保健服務的持續進步預計將推動創新並改善全球女性的治療結果。然而，要取得有意義的進展，就需要在研究、教育和宣傳工作方面持續合作和投資，以使婦女能夠掌控自己的健康和福祉。透過將婦女健康作為公共衛生議程和醫療保健系統的核心組成部分，努力實現一個所有婦女都能獲得照護和支持的未來，她們需要過著健康、充實的生活。

目錄

執行摘要

• 市場概況
• 命運之輪

研究方法論

• 資訊採購
• 二手和主要資料來源
• 市場規模估計
• 市場假設與限制

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題

主要市場洞察

• 技術分析
• 定價分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 總體經濟指標
• 頂級投資分析
• 成功的關鍵因素
• 競爭程度

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題
• 監管環境
• 波特分析
• 對未來顛覆的特別見解

依治療領域分類的全球女性健康治療市場

• 市場概況
• 荷爾蒙療法
• 避孕藥具
• 生殖健康藥物
• 其他

依適應症分類的全球女性健康治療市場

• 市場概況
• 停經
• 避孕
• 荷爾蒙相關癌症
• 生殖障礙
• 和別的

依配銷通路分類的全球女性健康治療市場

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局
• 和別的

全球女性健康治療市場規模（依地區）

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • MEA 的其餘部分

競爭格局

• 前 5 名企業比較
• 2021 年關鍵參與者的市場定位
• 主要市場參與者所採取的策略
• 最佳制勝策略
• 近期市集活動
• 主要公司市佔率（%），2021年

主要公司簡介

• Pfizer Inc. (United States)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• GlaxoSmithKline plc (United Kingdom)
• Merck & Co., Inc. (United States)
• AbbVie Inc. (United States)
• Eli Lilly and Company (United States)
• AstraZeneca plc (United Kingdom)
• Johnson & Johnson (United States)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Eisai Co., Ltd. (Japan)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Shionogi & Co., Ltd. (Japan)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Astellas Pharma Inc. (Japan)
• Sanofi (France)
• Bristol Myers Squibb Company (United States)
• Allergan plc (Ireland)

Global Women's Health Therapeutics Market size was valued at USD 12.98 billion in 2022 and is poised to grow from USD 13.70 billion in 2023 to USD 21.05 billion by 2031, growing at a CAGR of 5.52% in the forecast period (2024-2031).

The global women's health therapeutics market encompasses a diverse array of pharmaceuticals and treatments aimed at addressing the unique health needs and challenges faced by women across different stages of life. With an ever-growing focus on women's health issues, this market segment has seen significant expansion in recent years, driven by factors such as increasing awareness, advancements in medical technology, and evolving healthcare policies. From reproductive health and contraception to menopause management and osteoporosis treatment, the market offers a wide range of therapeutic options tailored to meet the specific needs of women. In recent times, there has been a heightened emphasis on research and development efforts targeting conditions that predominantly affect women, such as breast and cervical cancers, ovarian disorders, and autoimmune diseases like lupus and rheumatoid arthritis, among others. Additionally, there is a growing recognition of the importance of holistic approaches to women's health, which encompass not only medical interventions but also lifestyle modifications, mental health support, and access to education and preventive care. Despite significant progress, challenges persist in the women's health therapeutics market, including disparities in access to healthcare services, underrepresentation of women in clinical trials, and stigma surrounding certain health issues. Addressing these challenges requires a concerted effort from healthcare providers, policymakers, pharmaceutical companies, and advocacy groups to ensure equitable access to quality care and comprehensive support for women's health needs worldwide. Looking ahead, the future of the global women's health therapeutics market appears promising, with continued advancements in medical research, technology, and healthcare delivery expected to drive innovation and improve outcomes for women across the globe. However, achieving meaningful progress will require ongoing collaboration and investment in research, education, and advocacy efforts to empower women to take charge of their health and well-being. By prioritizing women's health as a central component of public health agendas and healthcare systems, we can work towards a future where all women have access to the care and support, they need to live healthy, fulfilling lives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Women's Health Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Women's Health Therapeutics Market Segmental Analysis

The global women's health therapeutics market is segmented into four major segments i.e. by therapeutic area, indication, distribution channel, and region. Based on type, it is divided into hormone therapies, contraceptives, reproductive health drugs, and others. Based on Indication, it is bifurcated as menopause, contraception, hormone-related cancers, reproductive disorders, and others. Based on distribution channel it is segregated into, hospital pharmacies, retail pharmacies, online pharmacies, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Drivers of the Global Women's Health Therapeutics Market

One significant driver propelling the growth of the global women's health therapeutics market is increasing awareness and advocacy for women's health issues. Over the past decade, there has been a notable surge in public awareness campaigns, educational initiatives, and policy efforts aimed at addressing women's health concerns. This heightened awareness has led to improved diagnosis rates, greater access to healthcare services, and increased demand for innovative therapies tailored to women's specific needs. Additionally, advancements in medical research and technology have expanded the scope of treatment options available, driving market growth further.

Restraints in the Global Women's Health Therapeutics Market

However, alongside these drivers, several restraints challenge the market's expansion. One notable restraint is the lingering stigma and cultural barriers surrounding women's health issues in many parts of the world. Societal taboos, misconceptions, and cultural norms can hinder women from seeking timely medical care or discussing their health concerns openly. Addressing these barriers requires comprehensive education and awareness campaigns, as well as culturally sensitive approaches to healthcare delivery.

Market Trends of the Global Women's Health Therapeutics Market

Moreover, a significant trend shaping the women's health therapeutics market is the growing emphasis on personalized medicine and precision healthcare. As our understanding of genetic predispositions and individual variations in drug responses improves, there is a shift towards tailored treatment approaches that consider each patient's unique biology, lifestyle, and health history. This trend is driving investments in genomic medicine, biomarker research, and targeted therapies, enabling more precise and effective interventions for women's health conditions. Additionally, the integration of digital health technologies, such as mobile apps and wearable devices, is enhancing patient engagement, remote monitoring, and data-driven healthcare decision-making, thereby transforming the delivery of women's health services.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Women's Health Therapeutics Market by Therapeutic Area

• Market Overview
• Hormone Therapies
• Contraceptives
• Reproductive Health Drugs
• and others

Global Women's Health Therapeutics Market by Indication

• Market Overview
• Menopause
• Contraception
• Hormone-related Cancers
• Reproductive Disorders
• and others

Global Women's Health Therapeutics Market by Distribution channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• and Others

Global Women's Health Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments